What are your top takeaways from ASTRO 2023?

1. LBA 05: Wong JS, et al. Patient-reported and toxicity results from the FABREC study: a multicenter randomized trial of hypofractionated vs. conventionally fractionated postmastectomy radiation therapy after implant-based reconstruction.

This is the first report of one of the two trials in North A...

1. Limited-stage SCLC – Radiation Dose

A phase 3 trial from China compared 54 vs. 45 Gy BID over 3 weeks (1.8 vs. 1.5 Gy/fraction). The dose-escalated arm involved a simultaneous integrated boost by increasing the dose to the gross disease. Overall survival and progression-free survival were both im...

The best presentation was the 10-year update of the IMPORT LOW trial - truly practice changing.

1. High Dose Hyperfractionated Thoracic Radiotherapy vs Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial. This study included 224 patients with SCLC randomized to 54 Gy in 30 fractions compared to standard dose of 45 Gy in 30 fractions. The pr...

1. The JAVELIN 100 Lee et al., PMID 33794205 highlights that we should not give immunotherapy concurrent with chemoradiation.
2. I think the Trilynx study shows in phase II Randomized study that Xevanipant improved survival. I believe this will be the next SOC.